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ABSTRACT
Chronic constipation is a medical gastrointestinal problem which can degrade patient’s quality of life. So 
far, the shifting pathophysiologic mechanism to colonic neuropathology has not been supported by diagnostic 
facility and therapy. Target therapy for chronic constipation related to enteric nervous system is still limited to 
study. Currently, the discovery of neurotrophin-3 has not shown any significant development needed in daily 
clinical practice. Until now study related to endoscopic full-thickness biopsy has not been done in human and 
waiting for its applications in daily practice. Targeted therapy for chronic constipation which is related to 
enteric nervous system is still limited to study. The discovery of neurotrophin-3, although currently on clinical 
trial phase II, still not showing any significant contribution in daily clinical practice. 
New pathophysiologic mechanism shifting the ‘idiopathic’ paradigm or ‘functional’ to colonic neuropathology 
has not been met with diagnostic modalities and therapy based on this knowledge. Study regarding endoscopic 
full-thickness biopsy to help revealing this novel mechanism has not been done in human. Henceforth, until 
now applied studies pertinent to this subject are longing in order for enteric neuron etiology can be firmly 
established Thus, in the future, translational study is demandingly needed for a firm establishment of diagnostic 
and therapeutic modalities to its currently evolving pathophysiology. 
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ABSTRAK 
Konstipasi kronis adalah masalah gastrointestinal yang dapat menurunkan kualitas hidup pasien secara 
bermakna. Sampai saat ini, pergeseran patofisiologi menjadi neuropatologi kolon belum didukung sarana 
dan prasarana diagnostik dan terapi yang memadai. Target terapi konstipasi kronis yang berhubungan 
dengan persarafan enterik masih terbatas di ranah penelitian. Baru-baru ini, penemuan neurotrophin-3 belum 
menunjukkan perkembangan signifikan yang dibutuhkan untuk praktek klinis sehari-hari. 
Mekanisme patofisiologis saat ini menunjukkan pergeseran paradigma dari idiopatik atau fungsional menuju 
neuropatologi kolon yang belum bersesuaian dengan modalitas diagnostik dan terapi yang tersedia. Studi 
menggunakan biopsi usus untuk membantu membuktikan adanya mekanisme patologis ini belum dilakukan 
pada manusia. Oleh karena itu masih banyak penelitian terkait  topik ini perlu dilakukan untuk membangun 
landasan dasar patofisiologi yang kokoh akan adanya etiopatologi neuron enterik. Untuk kedepannya, penelitian 
translasional dibutuhkan untuk meningkatkan modalitas diagnostik dan terapeutik berdasarkan patofisiologi ini.
Kata kunci: konstipasi kronis, kolon, persarafan enterik, neurotophin-3
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INTRODUCTION
Constipation is a medical gastrointestinal problem 
experienced virtually by everyone.1 Tack et al, stated 
that most people will experience constipation at least 
once in their lifetime.2 It is estimated that 2–27% of 
world population experienced constipation depends 
on the definition being used. Based on self-reporting, 
the prevalence of constipation is around 12%.2 Around 
10–20% population report one or more symptoms of 
constipation.3The prevalence of constipation vary 
geographically.4-6 Constipation is a common complaint 
found in our daily practice. It can lower the quality 
of life of the patient.6,7 Diagnosis and treatment that 
is established sometimes is not appropriate due to 
the attending physician’s lack of knowledge in when 
to consider a case as constipation. Data gathering 
regarding the incidence of constipation is sometimes 
ambiguous, between patient’s report (subjective) and 
the diagnosis based on Rome III criteria.8
Less satisfactory knowledge regarding the 
pathophysiology of chronic constipation is another 
problem in treating the patients. Up to now, chronic 
constipation not caused by mechanical etiology 
(e.g. colorectal tumor, stricture, anal fissure, 
intussusceptions) is considered solely as a functional 
or idiopathic problem without considering it as a 
wider entity, comprising problems in enteric nervous 
system. This causes the constipation experienced 
by the patient not further analyzed in daily clinical 
practice. In a literature study by Bassotti et al, it was 
stated that enteric glial cell (EGC) constantly played 
role in constipation.9 They also firmly stated that the 
paradigm constipation as idiopathic problems has 
to be discarded, and chronic constipation has to be 
considered as neurogliophatic problem (glial nervous 
system). That statement further should be an input in 
therapeutic choice in chronic constipation in the future.
This article focus on reviewing chronic constipation 
seen from the latest pathophysiology, diagnosis 
based on international clinical criteria (Rome III) 
and national consensus from Indonesian Society of 
Gastroenterology (ISG),6 and choice of therapy based 
on the latest evidence. It is aimed that this article 
can ignite research,especially translational research, 
particularly regarding the relationship between chronic 
constipation and diagnostic method as well as novel 
therapeutic choice, thus the treatment of chronic 
constipation will be more optimum in the future. 
PATHOPHYSIOLOGY: A REVIEW ON THE ROLE OF 
ENTERIC NERVOUS SYSTEM
According to Rome III criteria, chronic constipation 
is defined as constipation that has persisted for more than 
3 months, with onset of six months before the diagnosis 
is established.6,8,10 Chronic constipation can be caused 
by several factors that might be mechanic, metabolic, 
neuropathic, myopathic and idiopathic (functional).10 
The mechanical cause can easily be detected through 
colonoscopy with findings such as tumor, colon stricture, 
anal fissure and intussusceptions. Metabolic cause such 
as: hypothyroidism, diabetes mellitus, hypercalcaemia, 
hypokalemia, and uremia might need further testing band 
etiologic diagnosis is established based on hypothesis.
Enteric nervous system dysfunction has never 
been considered as etiology of chronic constipation in 
daily clinical practice.9 In the conditions in which no 
mechanical and metabolic etiology can be identified, 
the etiologic diagnosis will be averted to functional or 
idiopathic. Just like irritable bowel syndrome (IBS) 
which symptom is predominated by constipation, other 
possible causes of chronic functional constipation 
will not be further considered. Thus the diagnosis 
and therapy administered will be the same in every 
condition without further evaluation.
Recently, advance research has found the organic 
cause of various alimentary tract abnormalities that is 
previously considered as functional. Although the role 
of functional and psychosomatic cannot be undermined 
in these disorders, these organic findings in cases such 
as inflammatory bowel syndrome (IBS) and esophageal 
achalasia have shifted the paradigm in the field of 
gastroenterology and provide novel and more holistic 
therapeutic consideration in treating these diseases. 
Combination between functional and organic therapy 
as well as surgery has become the best choice in various 
gastrointestinal abnormalities.
Chronic constipation is one of the gastrointestinal 
problems with such shifting paradigm. During the 
90-s chronic constipation without mechanical cause 
has always been considered as functional or often 
considered as metabolic problem, however, studies 
from the last twenty years has proven that there is 
involvement of neurologic mechanism. Bassottiet al, 
summarized the evidence of nervous system (ENS) 
involvementas well as neurochemical imbalance 
in the colon.9 Additionally, other researchers also 
found the decreasing amount of intra ganglionic 
neuro filament, hypoganglionism in myenteric plexus 
and decreasing amount of interstitial cells of Cajal 
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(ICC) in constipation cases, although there are still 
disagreements between the available studies.
The complex pathophysiology of constipation is 
aided by the availability of colonic specimens from 
various types of constipation that is obtained through 
surgery or endoscopy.9,11 From those various specimens 
it is known that there are several ENS abnormality in 
all type of chronic constipations. From various types 
of constipations, slow transit constipation (STC) is 
one of the most scrutinized constipation because of 
its persistent nature to various medical treatments and 
often requires surgical treatment. In STC is known 
that there is a decreasing number of enteric neuron and 
ICC that is important for colonic motility.9 In another 
Basotti’s writing, it is stated that neuropathologic 
abnormality is not limited to colon but also in 
terminal ileum and this condition also cause chronic 
constipation.12
ENS abnormality has been proven in many studies as 
the etiology of chronic functional constipation.9 Further 
investigation showed that decreasing number of neuron 
was only found in sub mucosal plexus, while EGC lost 
could be found in the sub mucosal and myenteric plexus. 
The role of ICC apparently remained controversial, as 
Bassotti stated in his other report.13 The role of ICC and 
EGC was significant in constipation cases caused by 
colonic diverticular disease.9,14 Based on these studies, 
it could be concluded that the role of ENS differed in 
various causes of constipation. However, we could 
firmly state that ENS played important role in all chronic 
functional constipation cases.
Studies on ENS in chronic constipation still 
continue in various publications. However, not many 
researchers give attention to colonic neuropathology 
and its role in chronic constipation. Thus, opinions 
and findings only come from few researchers; among 
them is Bassotti who has published plenty of literature 
studies and reports in this field. In several of his 
publications, Bassotti stressed on the role of EGC in 
the incidence of chronic constipation.9,12-14
EGC represented the population of enteric ganglionic 
cells with the ratio of four to one compared to neuron. 
EGC itself has special mechanical function in colonic 
motility, participating in neurotransmission, promoting 
communication between synapses in enteric neuron, 
keeping homeostasis function of enteric neuron, keeping 
the immunity function and playing role in colonic 
inflammation process. Loss of EGC might decrease 
the motility and prolong the colonic transit. The role of 
EGC is very vital that several literatures consider EGC 
as pacemaker of colonic motility.
Loss of EGC plays role in the incidence of 
degeneration of enteric neuron population. Thus, 
based on Bassotti hypothesis, idiopathic phenomenon 
is not idiopathic but excessive apoptotic process of 
enteric neuron that causes chronic constipation in 
a patient. Many causes of this increasing apoptosis 
need to be studied further. Thus cellular, molecular, 
or pharmacological intervention can be done to the 
patient. Up to now, infections, inflammation, aging 
and xenobiotic are considered as the most important 
cause of apoptosis in cell’s life. Whether these causes 
also apply in the enteric neuron, still need to be studied 
further.
Bassotti et al, also tried to show the role of infection 
and colonic normal flora in the apoptosis of enteric 
neuron.9 In studies done by Sechi et al, it was stated that 
there was role of Mycobacterium avium and expression 
of prion in enteric neuron cell.15 Chronic infection cause 
destruction and increase of apoptosis in those cells. 
Other studies showed the role of colonic normal flora 
in ENS plasticity.16 Other factors suspected to play 
role is aging, a factor seen in daily clinical practice 
where plenty of geriatric populations experience 
chronic constipation, inappropriate use of laxative 
and chromosomal abnormality (genetic etiology).9,17 
The relationship between aging process with chronic 
constipation has been proven by several researchers 
and has been published in various scientific papers.17-19 
The relationship between normal colonic flora with 
ENS is the scientific basis why probiotic is used as 
therapy in chronic constipation.20,21
From several recent studies, it has been known that 
the chronic and excessive use of laxative can initiate 
heavy inertia in the colon. This inertia might decrease 
the amount and volume of ICC and ENS.22 This can 
lead to chronic constipation that is hard to treat with 
various medical treatments. In the future, this can 
be proven with preclinical studies (and later clinical 
trial) using per-endoscopic colonic biopsy with special 
technique (full-thickness biopsy).9,11
Several studies are still being conducted to 
find the cause of increasing apoptosis of enteric 
neuron.9,16 However, its relationship with chronic 
clinical constipation has not been totally proven. 
The bench to bedside evidences is still minimum to 
study constipation as a whole. Various studies only 
partly reveal information and facts, although every 
information is very important to conclude cellular 
theory regarding chronic constipation as a whole. For 
clinician in general, the relationship between cellular 
process, clinical symptoms, and (later) its utilization 
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in diagnostic method and treatment is of paramount 
importance as it might improve the medical service in 
patients with chronic constipation.
DIAGNOSIS:  FROM CONVENTIONAL TO 
PROBABILITY IN THE FUTURE
There are two aspects need to be reviewed regarding 
diagnosis of chronic constipation. Those are diagnostic 
criteria and infrastructure required to investigate the 
etiology. The Rome criteria have been used for a long 
time to establish the diagnosis of constipation. The 
term chronic is used if the constipation has occurred 
for 3 month and its onset started six months before the 
diagnosis has been established. Currently the Rome 
criteria that is employed is Rome III, released in 2006.10 
Below is the Rome III criteria being used to establish 
the diagnosis of constipation.
Table 1. Rome III criteria for the diagnosis of constipation10
Has to fulfill two of the following symptoms: 
a. Straining during at least 25% of defecations
b. Lumpy or hard stools in at least 25% of defecations
c. Sensation of incomplete evacuation for at least 25% of 
defecations
d. Sensation of anorectalobstruction/blockage for at least 25% 
of defecations
e. Manual maneuvers to facilitate at least 25% of defecations 
(e.g., digital evacuation, support of the pelvic floor)
f.  Fewer than three defecations per week
Loose stools are rarely present without the use of laxatives




Figure 2. Diagnostic guide for chronic constipation23 
 
Regarding the shift of paradigm from functional and idiopathic etiology to 
enteric nervous system etiology, we are expecting other diagnostic method which 
can be used. However, methods that are superior to colonoscopy in finding the 
etiology of constipation have not been available in many research and literature 
study. Absent of tumor, polyp or intussusceptions will only guide the diagnosis to 
functional or idiopathic constipation. Physiology test and colorectal transit time will 
only differ the colon transit time (whether it’s normal or slow). Apparently, we need to 
do further research to prove nervous system inflammation, as well as other various 
process occurring at the cellular or molecular level,to prove the role of ENS and 
neuron apoptosis as the cause of chronic constipation. 
One of the few studies succeeded in analyzing neuropathology in the colon is 
study by Neunlist et al.24 This study, for the first time, demonstrated the endoscopic 
full-thickness biopsy (eFTB) in pigs to see the amount of myenteric plexus and 
neuromuscular transmission in the pig’s colon with immunohystochemistry stain. The 
ability to see the colonic nervous system that consists of myenteric plexus, muscular 
proper, ganglion and myenteric neuron as a whole give hope for clinical trial to find 
out the role of ENS in every case of chronic constipation.24 
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Figure 1. Bristol stool chart29 
 
After data collection through thorough history taking and physical examination, 
especially when alarm signs and symptoms present, additional testing might be 
done. Some additional tests were including laboratory examination (peripheral blood 
examination, electrolyte, blood glucose level, thyroid function test and fecal 
analysis), imaging (plain abdominal x-ray, barium enema and CT colonography), 
colonoscopy, colorectal physiologic test, colonic transit test, anorectalmanometry, 
defecography and balon expulsion test.6,8,10 Although quite advanced, tests 
mentioned above can only evaluate fecal transit time in the colon and cannot surely 
establish the etiologic diagnosis of functional chronic constipation. 
The combination of history taking (including the Rome III criteria), physical 
examination, and conventional supportive test allow clinicians to diagnose chronic 
constipation as well as its etiology. Supportive test to assess the colon physiology 
and transit time might direct the physician to diagnose functional constipation as 
slow transit constipation or normal transit constipation.23 The chart below, created by 
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Recurrent stomach-ache or uncomfortable feeling for at least 
three days in a month, related to two or more of these acute 
symptoms:
- Relieve with defecati n
- Onset associated with a change in frequency of stool
- Onset associated with a change in form (appearance) of 
stool 
All points in Rome III criteria are the result from 
pati nts’ c mplaints which m ans the data c mes rom 
patient’s memory recall. Although these criteria also 
put recall bias into consideration, incorrect memory 
recall might still happ n during patients’ intervi w. It 
is not easy to remember 25% of defecations experience. 
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This criterion is often used to diagnose functional or 
idiopathic constipation. For more specific diagnosis 
of constipation, for example due to mechanical cause, 
normally other symptoms,such as stomachache, blood 
stool or vomiting occur . On the other hand, in cases 
of constipation due to metabolic causes, metabolic 
abnormality such as diabetes, hypothiroid, uremia and 
electrolit imbalance has to occur first. Drug induced 
constipation need to be suspected if during interview 
long-term use of drugs is found.
In national concencus, it states the role of Rome 
III criteria in diagnosing constipation. As alarm sign 
and symptoms, we have to be aware of the existence 
of hematoschezia, abdominal mass, familial history 
of IBD and colonic cancer, weight loss, anorexia, 
persistent vomiting and anemia. The consensus also 
states several physical examination associated with 
constipation, such as: (1) vital signs and nutritional 
status; (2) complete abdominal examination to evaluate 
presence of abdominal mass, abdominal distension, 
signs of acute abdomen, and bowel sounds; (3) digital 
rectal examination to assess the condition of sphincter 
ani, existence of hemorrhoid, rectal prolapses.6
Stool evaluation is important in estimating the colon 
transit time. The evaluation tool that is commonly 
employed is bristol stool chart that shows several fecal 
consistencies. The following picture shows bristol stool 
chart. Patients are asked which of these stools is his 
within the last one week.
After data collection through thorough history 
taking and physical examination, especially when 
alarm signs and symptoms present, additional testing 
might be done. Some additional tests were including 
laboratory examination (peripheral blood examination, 
electrolyte, blood glucose level, thyroid function test 
and fecal analysis), imaging (plain abdominal X-ray, 
barium enema and CT colonography), colonoscopy, 
colorectal physiologic test, colonic transit test, 
anorectalmanometry, defecography and balon 
expulsion test.6,8,10 Although quite advanced, tests 
mentioned above can only evaluate fecal transit time 
in the colon and cannot surely establish the etiologic 
diagnosis of functional chronic constipation.
The combination of history taking (including 
the Rome III criteria), physical examination, and 
conventional supportive test allow clinicians to 
diagnose chronic constipation as well as its etiology. 
Supportive test to assess the colon physiology and 
transit time might direct the physician to diagnose 
functional constipation as slow transit constipation or 
normal transit constipation.23 The chart below, created 
by American College of Gastroenterology (ACG), 
guides the diagnosis of chronic constipation.
Regarding the shift of paradigm from functional 
and idiopathic etiology to enteric nervous system 
etiology, we are expecting other diagnostic method 
which can be used. However, methods that are superior 
to colonoscopy in finding the etiology of constipation 
have not been available in many research and literature 
study. Absent of tumor, polyp or intussusceptions will 
only guide the diagnosis to functional or idiopathic 
constipation. Physiology test and colorectal transit 
time will only differ the colon transit time (whether 
it’s normal or slow). Apparently, we need to do further 
research to prove nervous system inflammation, as 
well as other various process occurring at the cellular 
or molecular levelto prove the role of ENS and neuron 
apoptosis as the cause of chronic constipation.
One of the few studies succeeded in analyzing 
neuropathology in the colon is study by Neunlist 
et al.24 This study, for the first time, demonstrated 
the endoscopic full-thickness biopsy (eFTB) in 
pigs to see the amount of myenteric plexus and 
neuromuscular transmission in the pig’s colon with 
immunohystochemistry stain. The ability to see the 
colonic nervous system that consists of myenteric 
plexus, muscular proper, ganglion and myenteric 
neuron as a whole give hope for clinical trial to find out 
the role of ENS in every case of chronic constipation.24
Two years after Neunlist et al published their work, 
Fritscher-Ravens et alfound that feasibility, safety, 
as well as wound recovery in eFTB technique is 
excellent in pigs’ colon (with sample of 30 pigs, more 
than sample used by Neunlist of 6 pigs) thus Neunlist 
hope of applying this method in human comes closer 
to manifest.25 The investigation for enteric nervous 
system etiology in constipation cases is hoped to be 
followed by findings in target therapy for constipation 
with enteric nervous system etiology.9
THERAPY: IMPLICATION TO PARADIGM SHIFT
As we have already known, the therapies for chronic 
constipation consist of various pharmacologic and 
non-pharmacologic treatments. In non-pharmacologic 
treatment, patients are advised to change their 
lifestyle, educations are given to increase fiber and 
fluid intake (30-50 cc/KgBW/day for normal person), 
increase the consumption of probiotic (Bifidobacteria 
animalislactis DN-173, for example ActiviaR), increase 
physical activity, avoid holding stool and routinely 
defecate.6
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Pharmacologic therapies are divided into bulk 
laxative (psyllium, methylcellulose), osmotic laxative 
(lactulose, stool softener), rectal enema (bisakodil, 
phosphate enema) and lubricant (CIC-2 chloride 
canal activator). Other pharmacologictherapies than 
laxative contain prokinetic agent (metocloparimde, 
domperidone). In patients with slow transit constipation, 
combination of stimulant laxative and prokinetic shows 
very good result, if combined with adequate non-
pharmacologic therapy. These empirical therapies have 
to be evaluated within 2-4 weeks. If no improvement 
occurs, further investigation is warranted. Therapy 
for underlying diseases with surgery might be done in 
constipation with mechanical etiology. This surgery is 
also indicated for functional constipation resistant to 
various medication.26,27
Other than standard therapies that are often given 
in daily clinical practice (e.g. lactulose, bisacodyl or 
polyethylen glycol (PEG)), there are several drugs that 
has been studied within the last ten years. Linaclotide 
is one of the drugs that has been widely published 
recently. This agent is guanilatecyclase receptor 
agonist type C that stimulates secretion of chloride and 
bicarbonate through increasing cGMP.28 Linactolide 
was proven to increase transit time in ascending 
colon, soften the stool consistency, and thus, decrease 
straining during defecation.29 Linactolide has entered 
phase III clinical trial and is known to be useful in 
constipation, predominantly in IBS cases and chronic 
constipation.28
Besides linaclotide, velusetrag and tegaserod have 
been studied in various clinical trials and show good 
efficacy as chronic constipation therapy. The existence 
of velusetrag is to lessen the side effect of tegaserod 
such as cardiovascular and stroke. Both are serotonin 
receptor agonist, in which velusetrag is more specific 
to 5-HT4 compared to tegaserode. Both are prokinetic 
agent to upper or lower digestive tractand can be used 
in patients with colon dismotility that manifest as 
chronic constipation.30
Based on latest data, apparently ‘functional’ 
paradigm shift to enteric nervous system has not yet 
been able to shift the conventional therapeutic choice 
being used in daily clinical practice. These three novel 
drugs for chronic constipation (mentioned above: 
linactolide, tegaserod and velusetrag) do not fully treat 
the enteric neuron apoptosis. Targeted therapy that has 
been mentioned several times in the pathophysiology 
review is still on research and development. One of 
the drugs is neurotrophin-3.
Neurotrophin-3 stimulates the growth and function 
of the enteric nervous system as well as colon transit 
time. In phase II clinical trial with placebo control, 
injection of neurotrophin-3 three times a week 
significantly increases the frequency of spontaneous 
movement in colon. This agent also improves other 
parameter of chronic constipation. However, as the 
development of this agent is not optimum, it is still not 
widely indicated in patients with chronic constipation.29 
Other than study by Parkman et al published in 2003, 
no other development regarding this drug is available. 
Up to now, this agent is not yet marketed or approved 
for chronic constipation.31
If the theory of normal flora related to the 
prevention of infection and nurture the amount and 
volume of enteric neuron is true, then therapy with 
pharmacobiotic is the direct implication of this 
theory. The theory itself has been used by researchers 
and clinicians in gastroenterology field; that the gut 
normal flora is very important in the wellbeing of 
enteric system. In various appraisals regarding latest 
pharmacotherapy for chronic constipation, therapy 
with probiotic is frequently mentioned. Normal flora 
proven to improve constipation by shortening colon 
transit time is Bifidobacteria lactis. Other strain, 
Bifidobacteria infantis is also proven to improve fecal 
profile (based on Bristol stool chart) and decrease 
straining during defecation.29
CONCLUSION
Novel pathophysiologic mechanism that shifts 
the ‘idiopathic’ paradigm or ‘functional’ to colonic 
neuropathology has not been met with diagnostic 
infrastructure and therapy based on this knowledge. 
Research regarding endoscopic full-thickness biopsy 
has not been done in human. Until now this still 
wait for application thus in the future enteric neuron 
etiology can be firmly established. Targeted therapy 
for chronic constipation that is related to enteric 
nervous system is still limited to research. The 
discovery of neurotrophin-3, although has reached 
clinical trial phase II, up until now has not shown 
any development that is significant in term of daily 
clinical practice. Therapy, whether its old or novel, 
for chronic constipation is still not based on enteric 
nervous system. In the future, translational research 
that is related to this topic has to be increased thus 
target based medical therapy choice is wider than 
before and surgery become the last modality in chronic 
constipation cases.
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